Clinical Trial Detail

NCT ID NCT02097225
Title Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

melanoma

Therapies

Dabrafenib + Onalespib + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST